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Abstract: The widespread of drug resistant Plasmodium falciparum has led to a rise in malaria-
associated mortality most especially in sub-Saharan Africa. Falciparum malaria was confirmed 
by microscopic examination of Giemsa-stained blood samples of patients who presented with 
fever in selected State Hospitals in Ogun State, Southwestern Nigeria. Molecular methods were 
employed to detect the markers of resistance of P. falciparum to Chloroquine, 
sulphadoxine/pyrimethamine,and artesunate  in Ogun State, Southwestern Nigeria. DNA was 
extracted from patient blood using the QiaAmp DNA Blood Minikit extraction method. Nested 
Polymerase Chain Reaction followed by Restriction Fragment Length Polymorphisms 
(PCR/RFLP) were used for the detection of P. falciparum chloroquine resistance transporter 
(Pfcrt), P. falciparum multidrug resistance 1 (pfmdr1), P. falciparum dihydrofolate reductase 
(Pfdhfr), P. falciparum dihydropteroate synthase (Pfdhps) and P. falciparum sarco/endoplasmic 
reticulum calcium-dependent ATPase (SERCA) PfATPase6 genes. Pfcrt (K76T ) Pfmdr1 (mdr 1 
) Pfdhfr (S108N), and Pfdhps (K540E) resistant genes were detected among the isolates while 
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resistant SERCAPfATPase6 gene which codes for artemisinin resistance was not detected in the 
population. 
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INTRODUCTION 
The main cause of the worsened 
malaria situation recorded in recent 
years has been the spread of drug-
resistant parasites. This has led to 
rising malaria-associated mortality, 
even though overall child mortality 
has fallen (Greenwood et al., 2005; 
Adefioye et. al., 2007).  
 
A major breakthrough in the search 
for the genetic basis of CQR in P. 
falciparum was the identification of 
PfCRT gene, which encodes a 
putative transporter or channel 
protein (Fidock et al., 2000). A 
K76T change on the PfCRT gene 
appears necessary for the resistance 
phenotype, and is the most reliable 
molecular marker of resistance 
among the various fifteen 
polymorphic amino acid positions in 
PfCRT gene associated with CQR in 
field isolates (Djimde et al., 2001; 
Plowe, 2003; Ojurongbe et al., 
2007). PfMDR1, is a homologue of 
the mammalian multiple drug 
resistance gene encoding a P-
glycoprotein on the chromosome 5 
of the P. falciparum. Several field 
studies indicated the positive 
association between the asparagine 
to tyrosine change at position 86 
(N86Y) and the chloroquine 
resistance both in vitro (Adagu and 
Warhurst, 1999; Basco and 
Ringwald, 2001; Pickard et al., 
2003) and in vivo (Ringwald and 
Basco, 1999; Basco and Ringwald, 
2001; Dorsey et al., 2001). However, 
other studies have cast doubts on this 
association (Pillai et al., 2001; 
Ojurongbe et al., 2007). 
 
Until recently, there has been a 
reliance on the cheap antimalarial 
drugs like Chloroquine and 
Sulphadoxine-Pyrimethamine. In 
2001, the World Health Organization 
(WHO) recommended Artemisinin 
combination Therapies (ACTs) as 
the first line of treatment for 
uncomplicated malaria (WHO, 
2001). The ACTs which include 
Artemether-lumefantrine (AL) and 
Amodiaquine (AQ) plus artesunate 
(AS) have been adopted for 
treatment of P. falciparum malaria in 
many African countries. To protect 
drugs from resistance, there is now 
clear evidence that combining them 
can improve their efficacy without 
increasing their toxicity (Olliaro and 
Taylor, 2002) and with the 
development of highly effective 
artemisinin derivatives, there is 
renewed hope for the treatment of 
malaria in the form of Artemisinin-
Based Combination therapy (ACT).  
 
Malaria remains uncontrolled and 
requires newer drugs and vaccines. 
Untill the malaria vaccine and newer 
class of antimalarial drugs become 
available, the existing drugs need to 
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be used cautiously. This is because 
the irrational use of antimalarial 
drugs can cause the drug resistant 
malaria. Effective usage of existing 
antimalarial drugs for malaria control 
strategies requires continuous input 
of the drug resistance pattern in the 
field. Resistance to antimalarial 
drugs can be assessed in vivo and 
also in vitro by parasite susceptibility 
assays or by the use of molecular 
techniques including Polymerase 
Chain Reaction (PCR) methods to 
detect genetic markers. 
 
Molecular studies using various 
markers can provide the advance 
information on the emergence of 
drug resistance pattern in the field 
and such can be used to design 
malaria control strategies. Using 
molecular studies, point mutations 
on the P. falciparum Chloroquine 
Resistant Transporter (PfCRT) and 
P. falciparum Multi-drug Resistant1 
(PfMDR1) genes have been reported 
to play an additional role for the 
chloroquine resistance in P. 
falciparum isolates while dhfr and 
dhps were associated with resistance 
to sulfadoxine-pyrimethamine 
(Ittarat  et al., 1994; Adagu and 
Warhurst, 1999). 
   
MATERIALS AND METHODS  
 
Sample Collection 
This study was carried out in Ogun 
State, located in the tropical zone of 
Southwestern Nigeria. Children 
between 1-15 years, pregnant women 
and other adults were included in this 
study. The blood samples were 
collected and analyzed between 
April 2008 and June 2009. Samples 
were collected from the four 
geopolitical zones of Ogun state viz: 
Sango – Ota (Yewa), Abeokuta 
(Egba),
 
Ijebu Ode (Ijebu) and 
Sagamu (Remo). Blood samples 
were collected for malaria screening 
from both fingerprick and 
venepuncture. About 2-5 ml of blood 
was then drawn (venepuncture) with 
a sterile disposable syringe and 
transferred to a heparinised 
centrifuge tube. The blood samples 
were transported to the laboratory at 
4
0
C. Drops of peripheral blood
 
were 
placed on 1.5 x 7.0-cm strips of 
Whatman (Brentford, United
 
Kingdom) 3MM filter paper so that 
the blood covered half the
 
length of 
the strip. The strips were air-dried 
and kept
 
in plastic bags until use.
 
 
 
Molecular Methods 
Polymerase Chain 
Reaction/Restriction fragment 
Length Polymorphism (PCR/RFLP) 
was used to determine the resistant 
genes and study the genetic 
diversity/genetic variation of 
antimalarial resistant Plasmodium 
falciparum.  DNA was extracted 
from patient blood spotted on the 
filter paper ("pre-culture") and 
cultured parasites ("post-culture") 
using the QiaAmp DNA Blood Mini 
kit Blood and Body Fluid Spin 
Protocol (Qiagen, Valencia, CA). 
The protocol for the extraction was 
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carried out according to 
manufacturer’s instruction.  
 
PCR for detection of Pfcrt gene 
The oligonucleotides
 
primers were 
designed from published sequences. 
For amplification of the 1.6-kb 
fragment of pfcrt, the lower primer
 
was 5'-
CCGTTAATAATAAATACAGGC-
3'.The upper primer was 5'-
CTTTTAAAAATGGAAGGGTGT-
3', (Dorsey et al.,
 
2001). The primary 
PCR components,
 
in a final volume 
of 20µL, was 2.5mM MgCl2, 640µM
 
deoxynucleotide triphosphate 
(dNTPs), buffer 10x, 10pM of each
 
primer, 1U of Taq polymerase 
(Ampli Taq Gold; Applied
 
Biosystems, Foster City, CA, USA) 
and 2µL of DNA samples.
 
The 
cycling protocol was as follows: 
95°C for 5 min for initial 
denaturation;
 
40 cycles of 94°C for 
30 s, 52°C for 40 s and 72°C
 
for 30 
s; and a final extension of 72°C for 5 
min.
 
 
 
Nested PCR and RFLP for Pfcrt 
mutation-specific detection  
For amplification of the 1.6kb 
fragment of pfcrt, a primary PCR 
was set up using the primers PFCF 
5'-
CCGTTAATAATAAATACAGGC-
3' and PFCR 5'-
CTTTTAAAATGGAAGGGTGT-3'. 
Product from primary PCR (2µl of 
10x dilution)
 
was used in a follow-
up, nested, allele-specific PCR
 
amplifications to detect the codons 
for pfcrt 76K or 76T. These
 
diagnostic PCR amplifications used a 
common inner primer pair
 
5'-
GGCTCACGTTTAGGTGGA-3' and 
5'-
TGAATTTCCCTTTTTATTTCCAA
A-3' (detects the 76T codon) or 5'-
GTTCTTTTAGC AAAAATCT-3'
 
(detects the 76K codon). The PCR 
stages for these diagnostic
 
amplifications were at 94°C for 5 
minutes, followed by 40
 
cycles at 
94°C for 30 seconds, 52°C for 40 
seconds,
 
and 72°C for 45 seconds 
and a final extension of 72°C for 5 
minutes. Purified genomic DNA 
from P. falciparum
 
clones HB3 
(chloroquine sensitive) and Dd2 
(chloroquine resistant)
 
were used as 
positive controls, and water, 
extracted uninfected
 
blood smears, 
and uninfected blood spots on filter 
paper were
 
used as negative controls. 
The PCR products from the 
amplification
 
reactions were 
evaluated by electrophoresis on 2% 
agarose gels containing ethidium 
bromide.
 
 10µl of the nested PCR 
product reaction mixture
 
were treated 
directly with 3U of the restriction
 
enzyme Apo I for 6 to 16 hours at 
50°C as recommended by the
 
manufacturer (New England Biolabs, 
Beverly, MA). The enzyme
 
Apo I 
recognise and cut the 76K codon, 
releasing fragment from product.
 
It 
does not cut the product containing 
the 76T codon found in
 
chloroquine-
resistant P. falciparum.
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PCR and RFLP for detection of 
Pfmdr1 gene 
Gene segments spanning codon 86 of 
the Pfmdr1 gene were amplified in 
20µl of
 
standard PCR mixture 
containing 5µl of extracted DNA
 
and 
primers MDR1 5'-ATGGGTAAA 
GAGCAGAAAGA-3' and MDR2 5'-
AACGCAAGTAATACATAAAGT
CA-3'.
 
The PCR amplification stages 
were at 94°C for 2 minutes,
 
followed 
by 35 cycles at 94°C for 20 seconds, 
52°C for
 
10 seconds, 48°C for 10 
seconds, and 60°C for 1.5 minutes.
 
A 
second, nested amplification from 
this segment was then performed
 
under the same PCR conditions 
using 1µl of the product
 
solution and 
primers MDR3 5'-
TGGTAACCTCAG-
TATCAAAGAA-3' and
 
MDR4 5'-
ATAAACCTAAAAAGGAACTGG-
3'. 
 
Presence of the mutant 86Y
 
codon 
was detected by digestion of 8µl of 
the second
 
amplification product 
solution with 1.5U of Afl III 
according to the manufacturer’s 
instruction (New England Biolabs). 
The products
 
of restriction digestion 
were separated by electrophoresis on
 
a 2% agarose gel and detected by 
staining with ethidium bromide.
 
 
 
PCR assays for the detection of 
Pfdhfr and Pfdhps genes 
Pfdhfr, and Pfdhps PCRs were 
performed as described by May and 
Meyer (2003a) and Marks et al 
(2004). For the Pfdhps PCR, two 
primers (primer Pfdhps-F 5-
ATGATTCTTTT TCAGATG-3_ 
and primer Pfdhps-R 5-
CCAATTGTGTGATTTGTCCAC-3 
were designed to amplify 747 bp of 
the region exhibiting mutations 
relevant to Sulphadoxine resistance. 
PCR was performed with a volume 
of 20µl (each primer at 0.2M, dNTPs 
at 200M, and 1U of Hotstar-Taq with 
the appropriate buffer [Qiagen, 
Valencia, Calif.] and MgCl2 at a final 
concentration of 2.0 mM) and 
approximately 80ng of template 
genomic human DNA, with parasite 
DNA concentrations corresponding 
to the parasite burden in the 
individual. After an initial 
denaturation (15 min at 95°C), 31 
cycles of 30s at 94°C, 40s at 53°C, 
and 1min at 72°C were run. 
Elongation of the amplicons was 
completed by a final cycle of 10min 
at 72°C. Subsequently, a nested PCR 
was performed to increase the yields 
of the specific amplicons using 
primers primer pfdhps-F1 (5-
GTTGAACCTAAACGTGCTG-3) 
and pfdhps-R1 (5-
ATTACAACATTTTGATCATTC-
3). 3µl of the primary PCR product 
was used in a reaction volume of 
25µl containing 0.2M of each 
primer, dNTPs at 200M, reaction 
buffer with MgCl2 at a final 
concentration of 2.0 mM, and 1U of 
Hotstar-Taq). In the nested PCR, a 
high initial annealing temperature 
(AT), which ensures a high level of 
specificity of initial primer binding, 
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is followed by a gradual decrease in 
the AT toward the pre-calculated 
optimal AT. The parameters 
consisted of an initial denaturation 
step (15 min at 95°C) and 43 cycles 
of 30s at 94°C, the AT for 40 s, and 
72°C for 1 min, in which the ATs 
were 65°C (5 cycles), 60°C (5 
cycles), 56°C (7 cycles), 54°C (13 
cycles), and 53°C (13 cycles). 
Fragment elongation was performed 
by use of a cycle of 10 min at 72°C. 
The amplicons were monitored for 
quality and the expected size on 1% 
ethidium bromide-stained agarose 
gels. Statistical analysis (_χ2 tests) 
was performed by the use of STATA 
software (version 8.2; Corp., College 
Station, Tex.). 
 
PCR and RPLP assay for (SERCA) 
PfATPase6 
P. falciparum positive samples were 
amplified by PCR using PfATPase6-
specific primary and nested primer 
pairs. DNA extract for each sample 
was subjected to nested PCR 
amplification with primers flanking 
nucleotide codon 2307of the 
PfATPase6 gene. Both the primary 
and secondary reactions comprised 
2µl template, 0.25µM primer, 
1.5mM MgCl2, 200µM dNTP’s, 1x 
PCR buffer and 1U Taq DNA 
polymerase, in 25µl reactions. 
Amplification cycles for both 
primary and secondary reactions 
consisted of an initial denaturation at 
94
0
C for 2 minutes, followed by 25 
cycles of denaturation at 94
0
C for 45 
seconds, annealing at 46
0
C for 45 
seconds and extension at 65
0
C for 1 
minute, final extension was run at 
65
0
C for 2 minutes.  For primary 
amplification, the primers are 
2307FW 5’-TGA GCA TGG CAC 
AAG TIT 3’; 2307RV- 5’TCA ATA 
ATA CCT AAT CCA CCT AAA 
TA-3’.For nested PCR the primers 
are FW-EN 5’-TGA GCA TGG 
TAG AAG TTT T-3’ and RV-EN 5’- 
TCA TCT GTA TTC TTA ATA 
ATA TTT AAA TCT GTA CTA-3’ 
(Zhang et al., 2008). Internal primers 
for the nested PCR amplification 
(2307FW-EN and 2307RV-EN, were 
engineered to create Csp6 I 
restriction sites. One site, at 
PfATPase6 nucleotide codon 1916, 
serves as the internal control for the 
restriction digestion assay, which is 
always cut by the enzyme. Csp6 I 
digestion assay comprised 4µl of 
secondary PCR amplicon (432bp), 
1x buffer and 1.5U of Csp6 I 
restriction enzyme, in 30µl reactions. 
Digestion assays were incubated for 
12 hours at 37 
0
C.  PCR amplicon 
and restriction digests were analyzed 
by electrophoresis on a 2% ethidium 
bromide-stained agarose gel and 
visualized under UV 
transillumination. Restriction digests 
were loaded in 15 µl volumes per 
lane. Band sizes were measured 
using Syngene gel imaging analysis 
software.
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RESULTS 
Prevalence of drug resistant molecular markers 
 
Table 1: Zonewise Prevalence of molecular markers of resistance to antimalarial 
drugs in P.  falciparum from Ogun State, Southwestern Nigeria.  
 
Zone No. of 
Isolate
s 
            Prevalence of resistance genes 
pfcrtK76T 
(%) 
Pfmdr1Y86N 
(%) 
PfdhfrS108N 
(%) 
pfdhpsK5
40E (%) 
pfATPaseS7
69N (%) 
Ijebu 20 9 (45) 10 (50) 3 (15) 0 (0) 0 (0) 
Yewa 43 28 (65.1) 30(69.8) 4 (9.3) 1 (2.3) 0 (0) 
Egba 25 5 (20.0) 12 (48) 4 (16) 1 (4) 0 (0) 
Remo 12 6 (50.0) 8 (66.7) 1 (8.3) 0 (0) 0 (0) 
Total 100 48 (48) 60 (60) 12 (12.0) 2 (2) 0 (0) 
Plate 4.1: DNA bands of wild type and mutated P.
falciparum chloroquine resistance genes
M
265bp
132bp
Plate 4.2: P. falciparum Multidrug Resistance 
Genes showing the wild type and mutated genes
165bp
325bp
M
 
                     
Plate 4.3: DNA band of Dihydrofolate reductase gene 
(DHFR 108)
322bp
708bp
M
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Plate 4.4: DNA band of Di hydropteroate synthase gene (DHPS 540)
M
441bp
756bp
M M
 
DISCUSSION 
One of the factors to be considered 
in the prophylaxis, treatment,
 
and 
control of Plasmodium falciparum 
malaria is the resistance
 
of parasite 
strains that may arise against 
virtually every drug
 
available. 
Identification of Pfcrt as the central 
determinant of chloroquine-resistant 
P. falciparum malaria provides a 
molecular marker that can be used 
for surveillance of resistance and to 
evaluate drug treatment and 
prophylaxis policies. The present 
results further support this role of the 
Pfcrt gene. Amplification products 
from all the chloroquine-sensitive
 
samples carried the codon for Pfcrt 
76K. Out of the
 
51 samples that were 
chloroquine-resistant by in vitro 
testing carried out in earlier studies,
 
48 were found to carry the 76T 
codon, 5 were found to contain
 
mixed 76T/76K codons, and 3 were 
discordantly found to contain
 
the 
76K codon. This finding 
corroborates with earlier findings 
where molecular markers of 
resistance were found in samples that 
gave in vivo resistance/drug failure 
(Djimde et al., 2001; Chen et al., 
2001; Happi et al., 2004). 
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The high prevalence of mutations at 
codons 76T, that code for 
chloroquine resistance in Nigerian P. 
falciparum isolates suggests that the 
population of P. falciparum that 
circulates in South-Western Nigeria 
has been selected by the long use of 
CQ. The overall picture emerging 
from this study is that resistance to 
this drug is abundant in south- 
Western Nigeria, and this finding 
strongly supports withdrawal of CQ 
as the first-line drug for treatment of 
falciparum malaria in Nigeria. This 
observation also supports the view 
that the Pfcrt
  
polymorphism at 
position 76 is in fact a significant 
factor
 
of CQ resistance, as shown in 
previous studies from Cameroon 
(Basco and Ringwald, 2001.),
 
Mali 
(Djimde et al., 2001), Mozambique 
(Mayor et al., 2001), Nigeria (Adagu 
and Warhurst, 2001), Sudan (Babiker 
et al., 2001), Uganda (Kyosiimire-
Lugemwa et al., 2002), Madagascar 
(Ariey et al., 2002),
 
Laos (Labbe et 
al., 2001), Papua New Guinea 
(Maguire et al., 2001), and Thailand 
(Chen et al., 2001; Jürgen and 
Christian, 2003). CQ resistance has 
been attributed to a single mutation 
at codon 76 in the Pfcrt gene 
(Djimde et al., 2001; Basco and 
Ringwald, 2001).  
It
 
has been observed that the Pfcrt 
K76 and the Pfmdr1 Y86 alleles
 
are 
closely associated in chloroquine 
resistant strains (Adagu and 
Warhurst, 1999). A similar 
observation was made in this study 
as all isolates carrying Pfcrt mutated 
allele were also positive for Pfmdr1 
mutated allele. However,
 
studies 
comparing the associations of the 
Pfmdr 1 variant
 
and the Pfcrt K76 
variant have shown that the impact 
of the
 
pfcrt gene was stronger than 
that of the pfmdr gene (Djimde et al., 
2001; Dorsey et al., 2001; Ojurongbe 
et al., 2007). It has been
 
suggested 
that the degree of chloroquine 
resistance is further modulated
 
by 
factors linked to genes other than 
Pfcrt or Pfmdr (Chen et al., 2001).
 
 
Molecular methods that detect 
genetic markers of drug resistance
 
are potentially powerful tools for 
tracking drug-resistant malaria.
 
In 
this study, the combination of Pfcrt 
and Pfmdr1 mutations
 
in isolates 
associated
 
with in vitro amodiaquine 
resistance was observed. Mutant 
PfcrtT76 and Pfmdr1Y86 alleles 
were observed in
 
48% and 60% of 
the samples, respectively. A previous
 
study in Sudan (Babiker et al., 2001) 
found that the mutant PfcrtT76 allele
 
is associated with amodiaquine 
treatment failure. The high 
prevalence of the mutant PfcrtT76 
allele (48%) and Pfmdr1 allele 
(60%) observed
 
in Ogun State, 
Nigeria confirms recent reports of 
the high prevalence
 
rate of this 
alleles in parasites obtained from 
similar studies (Happi et al., 2006)
 
and is also consistent with rates 
ranging from 60% to 100% reported
 
in other malaria-endemic regions 
(Maguire et al., 2001; Basco and 
Ringwald, 2001; Djimde et al 2001). 
The non-significant selection of the 
mutant PfcrtT76 by amodiaquine 
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may
 
be due to the high prevalence of 
this allele in the P. falciparum
 
population from South Western 
Nigeria. Selection of Pfmdr1Y86 by
 
amodiaquine has also been reported 
previously in the Gambia (Happi et 
al., 2003). Although the importance 
of point mutations in Pfcrt in 
producing
 
chloroquine resistance is 
beyond dispute (Basco and 
Ringwald, 2001; Maguire et al., 
2001; Chen et al., 2001) recent 
transfection
 
studies of Pfcrt have 
shown that isolates expressing the 
mutant
 
PfcrtT76 allele retain 
sensitivity to amodiaquine while 
showing a reduced
 
susceptibility to 
monodesethyl amodiaquine, the 
active metabolite of
 
amodiaquine 
(Happi et al., 2003). The selection of 
the mutant
 
PfcrtT76 and Pfmdr1Y86 
alleles indicates the primary 
involvement
 
of these two genes in 
the mediation of amodiaquine 
resistance. Thus, similar to 
chloroquine resistance, amodiaquine 
resistance in P. falciparum
 
may 
depend primarily on mutation(s) in 
Pfcrt and additional
 
mutations in 
Pfmdr1 or other Plasmodium genes 
may also have
 
significant roles in 
increasing resistance to the drug.
  
 
The combination of pfcrtT76 and 
pfmdr1Y86 mutations was associated
 
with amodiaquine treatment failure. 
These two alleles have been shown
 
to be in linkage disequilibrium in 
chloroquine-resistant isolates of
 
P. 
falciparum from The Gambia and 
Nigeria (Happi et al., 2003). The 
similarity in the chemical structures
 
of chloroquine and amodiaquine and 
their possible likely common mode 
of action suggests
 
that the molecular 
basis of resistance to these two drugs 
may
 
be similar.  
 
Resistance against Sulphadoxine and 
Pyrimethamine was observed in this 
study. Among the isolates analyzed 
for resistance markers, PfdhfrS108N 
and PfdhpsK540E genes coding for 
Pyrimethamine and Sulphadoxine 
respectively were detected. It has 
been earlier observed that Resistance 
to pyrimethamine is primarily 
conferred by a non-synonymous 
point mutation at codon 108 and is 
consecutively enhanced by mutations 
at codons 51 and 59 of the P. 
falciparum pfdhfr gene located on 
chromosome 4 (Bruce-Chwatt, 1985; 
Kublin et al., 2002). The enzyme is 
part of the folate pathway and, thus, 
of DNA replication. In this study 
genes that code for sulphadoxine and 
pyrimethamine resistance were 
detected among the isolates screened 
for markers of resistance against 
these drugs. PfdhfrS108N and 
PfdhpsK540E alleles were detected 
in 12 and 2 isolates respectively. 
 
On the basis of evolutionary theories, 
biological disadvantages are 
expected for parasites carrying 
resistance-mediating mutations in the 
absence of drug pressure. The fitness 
deficit conferred by the PfdhfrS108N 
mutation in the absence of 
pyrimethamine use is considered 
quite low. Enduring resistance in the 
absence of strong drug pressure 
implies that the expected decline in 
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the prevalence of resistant parasites 
is balanced by mechanisms that 
confer biological advantages with 
regard to survival fitness, replication 
and transmission probability, 
invasion, reproduction, and vector 
properties that favor transmission. 
As Sub-Saharan African countries 
are confronted with the rapid 
emergence of resistance against 
virtually every drug that is used for 
the treatment of P. falciparum, 
malaria drug pressure is considered 
to essentially promote the emergence 
of SP resistance, which is now 
widespread in East Africa, but also 
well recognized in West Africa.  
 
Selection for the Ser to Asn 
substitution at codon 108 of the 
Pfdhfr gene has been shown to be 
linked to parasite survival after 
treatment with pyrimethamine -
containing regimens (Plowe et al., 
1998; Marks et al., 2005). 
Accordingly, the high frequencies of 
resistant parasite populations have 
been attributed to increased 
pyrimethamine consumption (Marks 
et al., 2005). An Asp to Ile 
substitution at codon Pfdhfr51 
(PfdhfrN51I) and/or a Cys to Arg 
exchange at codon pfdhfr59 
(pfdhfrC59R) appears to enhance 
pyrimethamine resistance if one or 
both of these occur concurrently with 
PfdhfrS108N. PfdhfrS108N-N51I-
C59R is the combination of 
mutations most strongly associated 
with pyrimethamine resistance. Point 
mutations at codons 437 and 540 of 
the Pfdhps gene located on 
chromosome 8 of P. falciparum are 
considered responsible for 
sulphadoxine resistance. Pfdhps 
encodes a key enzyme in the folate 
pathway, as does Pfdhfr. The Ala to 
Gly substitution at position 437 
(PfdhpsA437G) is, in general, the 
first mutation to occur. In Africa this 
is followed by the Lys to Glu 
substitution at position 540 
(PfdhpsK540E), which confers 
higher levels of resistance. It was 
recently shown that the presence of 
the three Pfdhfr mutations combined 
with the two Pfdhps mutations 
(quintuple mutation) is strongly 
associated with SP resistance (Marks 
et al., 2005). 
 
Geographical clustering was reported 
for chloroquine-resistant Pfcrt 
(Wootton et al., 2002) and anti folate 
resistant Pfdhfr and Pfdhps 
haplotypes (Cortese et al., 2003), 
indicating distinct ancestral selection 
events in different areas. One 
important aspect in the possible 
setting leading to drug resistant 
parasites in Western Nigeria is the 
genetic background of the local 
parasite population. Multidrug-
resistant P falciparum is common, 
with a high rate of Pfcrt, Pfmdr1, 
Pfdhfr and Pfdhps resistance 
haplotypes. Thus, selection pressures 
were exerted on a heavily mutated 
genetic background. The several 
PfATPase6 haplotypes harbouring 
the S769N mutation indicate that 
selections of such mutants are 
therefore not impossible in the 
nearest future. As chloroquine and 
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SP are replaced
 
by more effective 
artemisinin-based combination 
therapies (ACTs),
 
strategies for 
monitoring (and, if possible, 
deterring) drug-resistant
 
malaria 
must be updated and optimized. In 
vitro methods for
 
measuring 
resistance will be critical for 
confirming and characterizing
 
resistance to ACTs. Molecular 
markers are useful for tracking
 
the 
emergence and dissemination of 
resistance and guiding treatment
 
policy where resistance is low or 
moderate. 
 
One hundred samples that were 
positive for P. falciparum by 
microscopy were subjected to PCR 
genotyping for estimating prevalence 
of the PfATPase codon S769N 
mutation. All the 100 (100%) 
isolates carried the artemisinin 
sensitive wild type allele, S769. This 
observation is similar to the ones 
observed in several African countries 
where artemisinin and its derivatives 
are used as first line of treatment of 
uncomplicated malaria (Basco and 
Ringwald, 2001; Djimde et al., 2001; 
Mayor et al., 2001; Adagu and 
Warhurst, 2001; Babiker et al., 2001; 
Kyosiimire-Lugemwa et al., 2002). 
However Artemisinin resistant genes 
have been detected by some workers 
especially in South Asia (Labbe et 
al., 2001; Maguire et al., 2001; Chen 
et al., 2001; Jürgen and Christian, 
2003). Artemisinin derivatives are an 
essential component of treatment 
against multidrug-resistant 
falciparum malaria. The genes that 
code for artemisinin resistance was 
not detected in any of the isolates 
screened for antimalarial resistance 
genes. Widespread multidrug-
resistant falciparum malaria led 
WHO to recommend combination 
drug therapy as first-line treatment, 
with formulations containing an 
artemisinin compound as policy 
standard. Artemisinin and its 
derivatives are the most potent and 
rapidly acting antimalarials. 
However, artemisinin resistance has 
been reported in murine models of 
malaria (Ferrer-Rodiriguez et al., 
2004; ambou et al., 2005), in the 
Thai-Cambodia border (Noedl et al., 
2009; Dondorp et al., 2009) and the 
western border of Thailand (Aung et 
al., 2012). Diligent surveillance is 
needed to monitor continued 
susceptibility to artemisinin 
derivatives in endemic areas.
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